<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE330nnn/GSE330529/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE330529</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Transcriptomic Profiling Identifies GPNMB as a Key Driver of Gastric Cancer Aggressiveness</name><description>We aimed to define the role of GPNMB in gastric cancer (GC) progression and its underlying mechanisms. Stable GPNMB-knockdown/overexpression GC cell models were established, and transcriptomic profiling identified the cAMP signaling pathway as a key downstream effector. GPNMB silencing significantly inhibited GC cell proliferation, invasion, induced G1 arrest and apoptosis, while overexpression activated the cAMP/PKA/CREB axis to upregulate c-Myc, Cyclin D1 and EMT markers, which was reversed by the PKA inhibitor H-89. GPNMB also promoted an immunosuppressive microenvironment via IL-6 and TGF-β upregulation and accelerated xenograft tumor growth. Our findings identify GPNMB as a critical driver of GC malignancy through the cAMP/PKA/CREB axis, representing a promising therapeutic target.</description><dates><publication>2026/05/17</publication></dates><accession>GSE330529</accession><cross_references><GSM>GSM9728226</GSM><GSM>GSM9728225</GSM><GSM>GSM9728228</GSM><GSM>GSM9728227</GSM><GSM>GSM9728224</GSM><GSM>GSM9728223</GSM><GPL>24676</GPL><GSE>330529</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>